Articles tagged with Clinical Trials
Administration of antenatal corticosteroids to late preterm babies was not linked to increased risk of neurodevelopmental problems by age 6. Long-term follow-up study suggests the medication may be safe for these high-risk infants.
A phase 3 clinical trial found that 96.7% of patients did not experience severe vaso-occlusive crises, and all remained hospitalization-free for at least one year after receiving the gene therapy CASGEVY.
Researchers at Baylor College of Medicine conducted a phase I clinical trial using CAR T cells engineered to target the HER2 protein, which is overexpressed on sarcoma cells. The therapy showed safety and associated with clinical benefit, with improved CAR T expansion and persistence.
The Alzheimer's disease treatment landscape is experiencing a significant shift, with numerous potential drugs making their way through clinical trials. Biomarkers have also emerged as a key area of focus, providing valuable information on the drug's impact and allowing for more precise guidance in future trials.
The FDA has approved the use of N-803, an immunotherapy drug, in combination with BCG for treating patients with non-muscle invasive bladder cancer who did not respond to conventional treatment. The approval is based on a trial led by UCLA's Dr. Karim Chamie, which showed improved outcomes and longer overall survival rates.
A randomized clinical trial found self-administered acupressure to be efficacious and cost-effective in reducing knee pain and improving mobility in middle-aged and older adults with probable osteoarthritis. The treatment also showed significant benefits in terms of quality of life.
A phase 3 trial shows that pembrolizumab significantly prolongs overall survival in high-risk kidney cancer patients. The treatment delays recurrences and helps patients live longer, with a 38% reduction in risk of death compared to placebo.
Researchers found that individuals from certain racial and ethnic groups are less likely to be eligible for Alzheimer's disease clinical trials due to lower amyloid levels at early stages of the disease. Amyloid buildup in the brain varies across different populations, contributing to underrepresentation in clinical trials.
The phase 2 study found an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a significant improvement over the baseline annualized growth velocity. The treatment was well-tolerated, and some patients showed excellent responses to vosoritide.
Researchers found that riociguat significantly improved blood pressure and reduced the risk of serious adverse events compared to a placebo treatment. The study showed promising results for this potential new treatment to manage complications from sickle cell disease, paving the way for larger clinical trials.
Researchers analyzed blood stem cells in mice with prior sepsis and found they were fully recovered but failed to respond to a second inflammatory stimulus, leading to inefficient immune cell production.
A new three-step prostate cancer screening method can detect aggressive cancers while minimizing the detection of insignificant ones. The study found that this approach reduces unnecessary diagnoses and may lead to improved mortality rates.
A study from the University of Gothenburg found that patient images are severely lacking in scientific articles on atopic dermatitis. This lack of visual aids hinders patients' ability to make informed decisions about their care, as they struggle to understand complex medical terminology and figures. The absence of images also affects ...
A phase I trial demonstrated AZD1390's manageable safety profile and preliminary efficacy in recurrent and newly diagnosed glioblastoma patients. The study showed improved overall survival, with a median of 12.7 months in patients who received higher doses of AZD1390.
A clinical trial found that a nasal spray called etripamil effectively and safely treated recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) in patients. The study showed that two-thirds of participants experienced relief within an hour, with an average time needed for symptom relief being 17 minutes.
A 10-minute virtual reality session significantly lessened pain in hospitalized patients with cancer, with sustained benefits even a day later. The study found that VR sessions had a greater impact than guided imagery, improving not only pain severity but also related issues like general distress.
A systematic review of 41 randomized clinical trials suggests that late-stage cancer incidence can be a suitable alternative end point to cancer-specific mortality in some cancer types, but not others. This finding has implications for multicancer screening tests and may change the way these trials are designed.
A new study found that high-dose influenza vaccine significantly improved humoral response in patients with heart failure or prior myocardial infarction. Vaccination remains crucial in preventing influenza-related complications in high-risk populations.
A telephone-based strategy improved guideline-directed medical therapy rates for outpatients with heart failure by 30 days, offering a low-cost solution for rural settings with limited access to care. This study suggests the potential for expanded remote healthcare initiatives to address health disparities.
A new study found that combining pelvic floor exercises with behavioral therapy can be more effective than current medical treatments in helping men with frequent urges to urinate. The Bladder Emptying Disorder Therapy (BEST) Trial showed significant improvements in symptoms and quality of life measures after just 12 weeks.
Researchers found that withdrawing aspirin one month after PCI significantly reduced major and minor bleeding incidents by 55% compared to dual antiplatelet therapy. The study, ULTIMATE-DAPT, showed no increase in adverse ischemic events, suggesting continuing aspirin may cause harm without benefit.
The randomized clinical trial demonstrates plozasiran's potential to reduce triglyceride levels in patients with severe hypertriglyceridemia. Additional studies are needed to determine its impact on complications associated with the condition.
A new approach to heart bypass surgery has been successfully tested, using non-invasive cardiac-CT scan images and AI-powered blood flow analysis. The trial showed a 99.1% feasibility rate, indicating that the procedure is safe and effective without invasive diagnostic catheterisation.
Most cancer drugs granted accelerated approval show no benefit in overall survival or quality of life within five years. Patients should be informed about the limited effectiveness of these drugs.
A new study found that inter-atrial shunts improve symptoms and outcomes in heart failure patients with reduced left ventricular ejection fraction (LVEF), but worsen outcomes in those with preserved LVEF. The device reduces high pressures in the left atrium, causing shortness of breath and hospitalizations.
A new oral vaccine for recurrent Urinary Tract Infections (UTIs) has been shown to prevent infections in over half of participants for up to nine years. The MV140 vaccine was found to be safe and effective, with no notable side effects reported.
In a preliminary report from an ongoing clinical trial, prostate cancer screenings using PSA, Kallikrein Panel, and MRI detected higher rates of cancer compared to no screening. The study found one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected in the screened group.
A randomized clinical trial found that PSA screening compared to no routine screening resulted in a small reduction in prostate cancer deaths after 15 years. The absolute reduction in deaths was modest, but the finding suggests potential benefits of PSA screening.
A simple blood test every five years is sufficient to screen low-risk men for prostate cancer, according to new research. Researchers found that only 0.13% of men with low PSA levels developed cancer after a decade.
A simple urine test can reduce the number of cystoscopies required to follow up high-risk bladder cancer patients by more than half. The test monitors for recurrence of bladder cancer by measuring levels of five target mRNAs and was found to be effective in picking up cancer recurrence before any disease was visible through a cystoscopy.
A handheld device developed by Osaka Metropolitan University's team can detect multiple bacterial species within an hour, including disease-causing E. coli and salmonella. The sensor uses organic metallic nanohybrids to distinguish electrochemical signals on the same screen-printed electrode chip.
Recent trials have shown that testing for tumour DNA in the blood can identify advanced bladder cancer patients who are less likely to relapse after surgery, allowing doctors to target treatments more effectively.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Global prostate cancer cases are projected to double from 1.4 million in 2020 to 2.9 million by 2040, with low- and middle-income countries seeing the highest increases. The number of annual deaths is predicted to rise by 85%, mainly in LMICs due to under-diagnosis.
A groundbreaking clinical study demonstrates the potential of fecal microbiota transplantation (FMT) to improve symptoms in patients with Parkinson's disease. After 12 months, participants who received healthy donor stool transplants showed significant improvement in motor symptoms and reduced constipation.
Patients with post-COVID condition exhibit lower aerobic capacity and muscle strength compared to control groups, indicating potential benefits of cautious exercise regimens. The study highlights the need for personalized exercise recommendations to mitigate further skeletal muscle deconditioning in PCC patients.
A new study by Fred Hutchinson Cancer Center found that 21.9% of people with cancer participate in some form of clinical research, including treatment trials and biorepository studies. Enrollment in treatment trials was particularly high at National Cancer Institute-designated centers.
Dr. Rhonda Voskuhl's groundbreaking research has shed light on the mechanisms underlying sex differences in MS, highlighting a gene on female sex chromosomes that promotes inflammation and brain-protective effects of estrogen. Her work may lead to new treatment approaches for MS.
The study reveals that smartphone-based cognitive assessments can provide reliable and valid results for diagnosing frontotemporal lobar degeneration. These findings suggest a scalable solution for remote evaluations, which may enhance early detection.
The latest issues of APA journals focus on treatment options for youth with irritability, exploring collaborative psychopharmacology approaches. Additionally, the studies examine disparities in the use of restraint among psychiatric patients.
Researchers developed a smartphone cognitive testing app that detects early signs of FTD in gene carriers before symptoms appear. The app was found to be comparable to gold-standard methods and may enable greater participation in clinical trials.
Researchers from Penn Medicine will share data on the latest advances in cancer science and medicine, including novel targets in the tumor microenvironment and the influence of the microbiome on cancer therapy. The presentation is part of the American Association for Cancer Research (AACR) Annual Meeting 2024.
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
A randomized clinical trial has shown that delaying surgical repair of inguinal hernias in preterm infants until after discharge from the NICU reduces serious adverse events. The study found a high likelihood of hernia resolution with late repair, allowing for quicker hospital discharge.
Dr. Chana Sacks is the new Editor-in-Chief of NEJM Evidence, focusing on providing high-quality, practice-changing evidence for medical professionals. The journal aims to change how medical professionals think about generating evidence while making clinical learning engaging and fun.
Researchers found a 32% vaccine uptake among patients asked about receiving the flu shot and a 41% uptake for those who received a pamphlet, watched a video, and were told about benefits. The study suggests a systematic approach to increase vaccine uptake among underserved populations.
A new series of essays explores the ethics and social issues raised by brain research, including post-trial obligations for human participants in neural-device trials. The studies reveal that injury and illness rob individuals of personal identity, while neuromodulation can restore it.
A new study found significant reductions in total symptom score and faster return to physical activity among concussed adolescents and young adults treated with branched chain amino acid supplementation. The study's findings provide important preliminary data for a larger trial of BCAA therapy.
Researchers are evaluating two prototype placebo rings in a study to determine their safety and usability for women. The goal is to inform the final design of a dual-purpose ring that can prevent both HIV and unplanned pregnancy for a month at a time.
Researchers have developed a new tool to help clinics recruit patients from more communities by analyzing nearby hospitals serving diverse populations. The approach aims to increase accessibility and diversity in cancer trials, with the potential to improve patient outcomes.
A new AI tool can predict which breast cancer patients are at risk of chronic arm swelling after surgery and radiotherapy. The tool, developed by international researchers, uses machine learning algorithms to analyze patient data and provides easily understandable explanations for doctors and patients.
Adding ribociclib to hormone therapy improves invasive disease-free survival by 90.4% at three years, distant disease-free survival by 90.8%, and recurrence-free survival by 91.7%. The study found a 25% relative reduction in recurrence rate for patients with stage 2 or 3 HR-positive, HER2-negative early breast cancer.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A recent study found that digital reminders for flu vaccination increased vaccination rates among older adults in Denmark by one percentage point. However, it did not improve clinical outcomes, including hospitalization and death rates.
A combination of short-course hormonal therapy and stereotactic body radiation therapy has been shown to be safe and effective in treating metastatic prostate cancer. In a preliminary study, 50% of patients remained recurrence-free six months after treatment, with less than a quarter experiencing severe side effects.
A new acceptable practice standard for hypofractionated post-prostatectomy radiotherapy has been established based on the NRG Oncology trial findings. The study showed that HYPORT was non-inferior to COPORT in terms of late GI or GU toxicity, with greater short-term GI toxicity associated with HYPORT but resolving at 6 months following...
The RUBY Part 2 trial shows significant improvement in progression-free survival for patients with primary advanced or recurrent endometrial cancer treated with dostarlimab. Dostarlimab plus niraparib plus carboplatin/paclitaxel demonstrates a role for PARP inhibitor maintenance in improving patient outcomes.